NYSE:AGE

AgeX Therapeutics Competitors

$1.31
0.00 (0.00 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.30
$1.35
50-Day Range
$1.31
$1.90
52-Week Range
$0.67
$3.93
Volume298,397 shs
Average Volume309,050 shs
Market Capitalization$49.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5

Competitors

AgeX Therapeutics (NYSE:AGE) Vs. MDNA, SLGL, XERS, ETON, ITRM, and CKPT

Should you be buying AGE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to AgeX Therapeutics, including Medicenna Therapeutics (MDNA), Sol-Gel Technologies (SLGL), Xeris Pharmaceuticals (XERS), Eton Pharmaceuticals (ETON), Iterum Therapeutics (ITRM), and Checkpoint Therapeutics (CKPT).

Medicenna Therapeutics (NASDAQ:MDNA) and AgeX Therapeutics (NYSE:AGE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares Medicenna Therapeutics and AgeX Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicenna TherapeuticsN/A-40.19%-37.66%
AgeX Therapeutics-582.11%-932.89%-207.13%

Risk and Volatility

Medicenna Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, AgeX Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Insider and Institutional Ownership

3.9% of Medicenna Therapeutics shares are held by institutional investors. Comparatively, 13.2% of AgeX Therapeutics shares are held by institutional investors. 3.3% of AgeX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Medicenna Therapeutics and AgeX Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A$-6,220,000.00($0.19)-19.42
AgeX Therapeutics$1.73 million28.73$-12,150,000.00N/AN/A

Medicenna Therapeutics has higher earnings, but lower revenue than AgeX Therapeutics.

Analyst Ratings

This is a summary of current ratings and target prices for Medicenna Therapeutics and AgeX Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicenna Therapeutics00403.00
AgeX Therapeutics0000N/A

Medicenna Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 171.00%. Given Medicenna Therapeutics' higher probable upside, equities analysts clearly believe Medicenna Therapeutics is more favorable than AgeX Therapeutics.

Summary

Medicenna Therapeutics beats AgeX Therapeutics on 6 of the 11 factors compared between the two stocks.

Sol-Gel Technologies (NASDAQ:SLGL) and AgeX Therapeutics (NYSE:AGE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Insider & Institutional Ownership

30.9% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 13.2% of AgeX Therapeutics shares are held by institutional investors. 3.3% of AgeX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Sol-Gel Technologies and AgeX Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sol-Gel Technologies$22.90 million8.49$-24,610,000.00($1.26)-7.57
AgeX Therapeutics$1.73 million28.73$-12,150,000.00N/AN/A

AgeX Therapeutics has lower revenue, but higher earnings than Sol-Gel Technologies.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sol-Gel Technologies and AgeX Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sol-Gel Technologies00203.00
AgeX Therapeutics0000N/A

Sol-Gel Technologies presently has a consensus target price of $21.00, indicating a potential upside of 120.13%. Given Sol-Gel Technologies' higher possible upside, research analysts plainly believe Sol-Gel Technologies is more favorable than AgeX Therapeutics.

Profitability

This table compares Sol-Gel Technologies and AgeX Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sol-Gel Technologies-273.92%-48.54%-42.14%
AgeX Therapeutics-582.11%-932.89%-207.13%

Volatility and Risk

Sol-Gel Technologies has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, AgeX Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Summary

Sol-Gel Technologies beats AgeX Therapeutics on 7 of the 12 factors compared between the two stocks.

AgeX Therapeutics (NYSE:AGE) and Xeris Pharmaceuticals (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for AgeX Therapeutics and Xeris Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AgeX Therapeutics0000N/A
Xeris Pharmaceuticals02102.33

Xeris Pharmaceuticals has a consensus target price of $13.00, indicating a potential upside of 300.00%. Given Xeris Pharmaceuticals' higher possible upside, analysts clearly believe Xeris Pharmaceuticals is more favorable than AgeX Therapeutics.

Earnings and Valuation

This table compares AgeX Therapeutics and Xeris Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AgeX Therapeutics$1.73 million28.73$-12,150,000.00N/AN/A
Xeris Pharmaceuticals$2.72 million71.41$-125,580,000.00($4.81)-0.68

AgeX Therapeutics has higher earnings, but lower revenue than Xeris Pharmaceuticals.

Risk and Volatility

AgeX Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Xeris Pharmaceuticals has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.

Profitability

This table compares AgeX Therapeutics and Xeris Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AgeX Therapeutics-582.11%-932.89%-207.13%
Xeris Pharmaceuticals-2,037.97%-435.27%-91.81%

Insider and Institutional Ownership

13.2% of AgeX Therapeutics shares are held by institutional investors. Comparatively, 69.3% of Xeris Pharmaceuticals shares are held by institutional investors. 3.3% of AgeX Therapeutics shares are held by company insiders. Comparatively, 6.1% of Xeris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Xeris Pharmaceuticals beats AgeX Therapeutics on 10 of the 12 factors compared between the two stocks.

AgeX Therapeutics (NYSE:AGE) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares AgeX Therapeutics and Eton Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AgeX Therapeutics$1.73 million28.73$-12,150,000.00N/AN/A
Eton Pharmaceuticals$460,000.00421.00$-18,320,000.00($1.03)-7.68

AgeX Therapeutics has higher revenue and earnings than Eton Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and target prices for AgeX Therapeutics and Eton Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AgeX Therapeutics0000N/A
Eton Pharmaceuticals00203.00

Eton Pharmaceuticals has a consensus price target of $12.00, indicating a potential upside of 51.71%. Given Eton Pharmaceuticals' higher probable upside, analysts clearly believe Eton Pharmaceuticals is more favorable than AgeX Therapeutics.

Insider and Institutional Ownership

13.2% of AgeX Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Eton Pharmaceuticals shares are owned by institutional investors. 3.3% of AgeX Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares AgeX Therapeutics and Eton Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AgeX Therapeutics-582.11%-932.89%-207.13%
Eton PharmaceuticalsN/A-310.64%-152.51%

Risk and Volatility

AgeX Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Summary

Eton Pharmaceuticals beats AgeX Therapeutics on 8 of the 12 factors compared between the two stocks.

AgeX Therapeutics (NYSE:AGE) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Valuation & Earnings

This table compares AgeX Therapeutics and Iterum Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AgeX Therapeutics$1.73 million28.73$-12,150,000.00N/AN/A
Iterum Therapeutics$40,000.004,791.97$-103,130,000.00($7.10)-0.15

AgeX Therapeutics has higher revenue and earnings than Iterum Therapeutics.

Volatility and Risk

AgeX Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for AgeX Therapeutics and Iterum Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AgeX Therapeutics0000N/A
Iterum Therapeutics02202.50

Iterum Therapeutics has a consensus price target of $3.25, indicating a potential upside of 203.74%. Given Iterum Therapeutics' higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than AgeX Therapeutics.

Insider & Institutional Ownership

13.2% of AgeX Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of Iterum Therapeutics shares are owned by institutional investors. 3.3% of AgeX Therapeutics shares are owned by company insiders. Comparatively, 22.1% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares AgeX Therapeutics and Iterum Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AgeX Therapeutics-582.11%-932.89%-207.13%
Iterum TherapeuticsN/AN/A-179.51%

Summary

Iterum Therapeutics beats AgeX Therapeutics on 8 of the 12 factors compared between the two stocks.

AgeX Therapeutics (NYSE:AGE) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Valuation & Earnings

This table compares AgeX Therapeutics and Checkpoint Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AgeX Therapeutics$1.73 million28.73$-12,150,000.00N/AN/A
Checkpoint Therapeutics$1.71 million110.40$-24,710,000.00($0.70)-3.59

AgeX Therapeutics has higher revenue and earnings than Checkpoint Therapeutics.

Volatility and Risk

AgeX Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for AgeX Therapeutics and Checkpoint Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AgeX Therapeutics0000N/A
Checkpoint Therapeutics00303.00

Checkpoint Therapeutics has a consensus price target of $17.6667, indicating a potential upside of 603.85%. Given Checkpoint Therapeutics' higher probable upside, analysts plainly believe Checkpoint Therapeutics is more favorable than AgeX Therapeutics.

Insider & Institutional Ownership

13.2% of AgeX Therapeutics shares are owned by institutional investors. Comparatively, 18.8% of Checkpoint Therapeutics shares are owned by institutional investors. 3.3% of AgeX Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Checkpoint Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares AgeX Therapeutics and Checkpoint Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AgeX Therapeutics-582.11%-932.89%-207.13%
Checkpoint Therapeutics-2,032.05%-100.54%-75.09%

Summary

Checkpoint Therapeutics beats AgeX Therapeutics on 8 of the 12 factors compared between the two stocks.


AgeX Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medicenna Therapeutics logo
MDNA
Medicenna Therapeutics
0.7$3.69flat$197.59 millionN/A-18.45High Trading Volume
News Coverage
Gap Up
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$9.54flat$194.52 million$22.90 million-7.17Upcoming Earnings
Increase in Short Interest
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$3.25flat$194.24 million$2.72 million-0.82News Coverage
Eton Pharmaceuticals logo
ETON
Eton Pharmaceuticals
1.3$7.91flat$193.66 million$460,000.00-6.65Upcoming Earnings
News Coverage
Iterum Therapeutics logo
ITRM
Iterum Therapeutics
1.3$1.07flat$191.68 million$40,000.00-0.26Upcoming Earnings
News Coverage
Checkpoint Therapeutics logo
CKPT
Checkpoint Therapeutics
1.2$2.51flat$188.78 million$1.71 million-5.46Earnings Announcement
Analyst Revision
News Coverage
Gap Up
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.5$3.63flat$186.54 million$10.64 million-0.97Earnings Announcement
Analyst Report
Insider Selling
Analyst Revision
News Coverage
Gap Up
Marker Therapeutics logo
MRKR
Marker Therapeutics
1.5$2.35flat$186.36 million$210,000.00-4.27Upcoming Earnings
Analyst Revision
Zynerba Pharmaceuticals logo
ZYNE
Zynerba Pharmaceuticals
1.3$4.49flat$185.22 million$90,000.00-2.43Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Novan logo
NOVN
Novan
1.6$1.22flat$185.02 million$4.90 million-5.55Analyst Report
Decrease in Short Interest
Lannett logo
LCI
Lannett
2.0$4.43flat$183.41 million$545.74 million-6.15Earnings Announcement
News Coverage
Osmotica Pharmaceuticals logo
OSMT
Osmotica Pharmaceuticals
1.1$2.91flat$182.12 million$240.03 million-3.16Upcoming Earnings
News Coverage
IMV logo
IMV
IMV
0.8$2.66flat$180.11 million$430,000.00-5.78Upcoming Earnings
Equillium logo
EQ
Equillium
1.9$6.03flat$175.11 millionN/A-3.84Upcoming Earnings
Lantern Pharma logo
LTRN
Lantern Pharma
1.2$15.62flat$174.65 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Enochian Biosciences logo
ENOB
Enochian Biosciences
0.3$3.63flat$173.38 millionN/A0.00Upcoming Earnings
Gap Up
NuCana logo
NCNA
NuCana
1.5$3.57flat$173.13 millionN/A-3.53News Coverage
Gap Up
Milestone Pharmaceuticals logo
MIST
Milestone Pharmaceuticals
1.4$5.73flat$171.02 millionN/A-2.44Upcoming Earnings
Analyst Upgrade
Jaguar Health logo
JAGX
Jaguar Health
0.9$1.31flat$170.34 million$5.78 million-0.19Analyst Upgrade
Aptinyx logo
APTX
Aptinyx
1.4$2.54flat$170.10 million$3.67 million-2.02Upcoming Earnings
Biofrontera logo
BFRA
Biofrontera
1.2$5.94flat$168.45 million$35.02 million-7.71Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
Tyme Technologies logo
TYME
Tyme Technologies
1.3$1.29flat$168.25 millionN/A-5.86
Strongbridge Biopharma logo
SBBP
Strongbridge Biopharma
1.5$2.45flat$165.49 million$21.71 million-2.69Upcoming Earnings
News Coverage
OptiNose logo
OPTN
OptiNose
1.6$3.10flat$164.65 million$34.63 million-1.41Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
scPharmaceuticals logo
SCPH
scPharmaceuticals
1.3$6.01flat$164.40 millionN/A-3.71Upcoming Earnings
Gap Up
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.06flat$162.64 million$15.96 million-2.46Earnings Announcement
Genprex logo
GNPX
Genprex
1.2$3.42flat$161.99 millionN/A-5.61Upcoming Earnings
News Coverage
ObsEva logo
OBSV
ObsEva
1.4$2.80flat$161.15 millionN/A-1.12Earnings Announcement
News Coverage
Gap Up
180 Life Sciences logo
ATNF
180 Life Sciences
0.3$8.93flat$161.03 millionN/A0.00
DiaMedica Therapeutics logo
DMAC
DiaMedica Therapeutics
1.3$8.55flat$160.62 million$500,000.00-11.25Earnings Announcement
Satsuma Pharmaceuticals logo
STSA
Satsuma Pharmaceuticals
1.5$5.09flat$160.48 millionN/A-1.93Upcoming Earnings
Analyst Upgrade
BioLineRx logo
BLRX
BioLineRx
1.6$3.72flat$159.31 millionN/A-1.60Analyst Report
Gap Down
Exicure logo
XCUR
Exicure
1.5$1.81flat$159.27 million$1.30 million-6.96Upcoming Earnings
News Coverage
Heat Biologics logo
HTBX
Heat Biologics
1.6$6.25flat$158.81 million$3.05 million0.00Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Enlivex Therapeutics logo
ENLV
Enlivex Therapeutics
1.4$10.04flat$158.23 millionN/A-13.57
Clearside Biomedical logo
CLSD
Clearside Biomedical
1.3$2.72flat$156.62 million$2.17 million-8.50News Coverage
InflaRx logo
IFRX
InflaRx
1.4$3.62flat$156.49 millionN/A-2.21
Calithera Biosciences logo
CALA
Calithera Biosciences
1.8$2.09flat$154.76 million$22.25 million-1.51Earnings Announcement
News Coverage
Galera Therapeutics logo
GRTX
Galera Therapeutics
1.6$6.08flat$153.54 millionN/A-1.74Upcoming Earnings
Tiziana Life Sciences logo
TLSA
Tiziana Life Sciences
1.2$2.38flat$152.84 millionN/A-79.33
Abeona Therapeutics logo
ABEO
Abeona Therapeutics
1.6$1.54flat$152.52 million$3 million-1.48Analyst Revision
Oncolytics Biotech logo
ONCY
Oncolytics Biotech
1.2$2.86flat$151.13 millionN/A-3.53Upcoming Earnings
ContraFect logo
CFRX
ContraFect
1.4$3.82flat$150.25 millionN/A-1.43Increase in Short Interest
Analyst Revision
OncoSec Medical logo
ONCS
OncoSec Medical
1.6$4.02flat$149.38 millionN/A-1.63
Liminal BioSciences logo
LMNL
Liminal BioSciences
1.1$4.79flat$143.43 million$3.70 million-1.63Upcoming Earnings
SCYNEXIS logo
SCYX
SCYNEXIS
1.4$6.87flat$141.74 million$120,000.00-1.85Upcoming Earnings
Analyst Revision
Catalyst Biosciences logo
CBIO
Catalyst Biosciences
1.5$4.51flat$141.39 million$10,000.00-1.41Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Onconova Therapeutics logo
ONTX
Onconova Therapeutics
1.5$0.59flat$140.74 million$2.18 million-0.40Upcoming Earnings
Orgenesis logo
ORGS
Orgenesis
0.3$5.66flat$138.17 million$33.26 million1.22Upcoming Earnings
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Anixa Biosciences logo
ANIX
Anixa Biosciences
1.4$4.37flat$137.35 million$250,000.00-9.50
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.